• EpiCept Corp., of Tarrytown, N.Y., said it attained targeted enrollment in a Phase IIb trial of EpiCept NP-1, a topical cream formulation of 4 percent amitriptyline and 2 percent ketamine, in chemotherapy-induced peripheral neuropathy. The six-week study has enrolled more than 400 patients, with a primary endpoint of change in average daily neuropathy intensity scores from baseline. Top-line data are expected by the end of this year.

• NovaBay Pharmaceuticals Inc., of Emeryville, Calif., said it has completed enrollment in its Phase IIa proof-of-concept trial of Aganocide (NVC-422) for the treatment of impetigo, a highly contagious skin infection afflicting more than 1 million people annually in the U.S., primarily children and infants. The double-blind, randomized, sequential group study evaluated the safety and efficacy of Aganocide in 120 patients ages 2 to 12 at clinical centers in the Dominican Republic. Preliminary results of the trial will be released in July. NovaBay is partnering on the trial with Galderma SA, of Fort Worth, Texas.

• Oncolytics Biotech Inc., of Calgary, Alberta, said that the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio has started patient enrollment in a U.S. Phase II trial using intravenous administration of Reolysin in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer. The trial (REO 017) is part of a broad preclinical and clinical collaboration with the center that will involve up to five, open-label, Phase II studies exploring the use of Reolysin in combination with chemotherapy for various cancer indications.